



**MERZ NORTH AMERICA ANNOUNCES THE
ACQUISITION OF INTELLECTUAL PROPERTY
ASSETS RELATING TO DEOXYARBUTIN**

Merz North America, a specialty healthcare company that develops and commercializes innovative treatment solutions in dermatology, aesthetics and neurosciences, announces additional investment in the future of its U.S. aesthetics business.

Merz North America
Mariana Smith
Corporate Communications
4215 Tudor Lane
Greensboro, NC 27410
Office (336) 217-2636
Cell (615) 631-6795
msmith@merzusa.com

www.merzusa.com

GREENSBORO, N.C. – BUSINESS WIRE – Merz North America, Inc. today announced that it has acquired two patent applications relating to the skin-lightening agent deoxyArbutin (dA) from Lasya, Incorporated. deoxyArbutin (dA) is a novel tyrosinase inhibitor shown to have effect on skin-lightening and brightening.

This acquisition includes both U.S. and international patent filings. Under the terms of the agreement, Merz North America will direct all prosecution of these patent filings and will assume the full cost and responsibility for future development and commercialization worldwide. The specific terms of the acquisition, including upfront and milestone payments, remain confidential.

“The acquisition of these patent applications is an important step toward securing the rights to develop and commercialize a proprietary formulation of deoxyArbutin (dA) in the U.S. market,” said Bill Humphries, president & CEO of Merz North America. “As we continue to strengthen and expand our presence in the U.S. aesthetics space, Merz North America remains committed to providing patients and physicians with new products that set the standard for quality and innovation in aesthetic medicine.”

About Merz North America

Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients’ lives. For more than 100 years, the development of our products has been based on Merz’s commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses, and they have assumed a leading role in the field of Alzheimer’s disease research. Founded in 1908, Merz Pharma Group is a privately owned company headquartered in Frankfurt, Germany.

For more information about Merz or the Company's products, please visit www.merzusa.com.

Contact:

Merz North America
Mariana Smith
Corporate Communications
4215 Tudor Lane
Greensboro, NC 27410
Office (336) 217-2636
msmith@merzusa.com